Skip to main content

Testosterone supplementation in heart failure: a meta-analysis.

Publication ,  Journal Article
Toma, M; McAlister, FA; Coglianese, EE; Vidi, V; Vasaiwala, S; Bakal, JA; Armstrong, PW; Ezekowitz, JA
Published in: Circ Heart Fail
May 1, 2012

BACKGROUND: Low testosterone is an independent predictor of reduced exercise capacity and poor clinical outcomes in patients with heart failure (HF). We sought to determine whether testosterone therapy improves exercise capacity in patients with stable chronic HF. METHODS AND RESULTS: We searched Medline, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (1980-2010). Eligible studies included randomized controlled trials (RCTs) reporting the effects of testosterone on exercise capacity in patients with HF. Reviewers determined the methodological quality of studies and collected descriptive, quality, and outcome data. Four trials (n=198; men, 84%; mean age, 67 years) were identified that reported the 6-minute walk test (2 RCTs), incremental shuttle walk test (2 RCTs), or peak oxygen consumption (2 RCTs) to assess exercise capacity after up to 52 weeks of treatment. Testosterone therapy was associated with a significant improvement in exercise capacity compared with placebo. The mean increase in the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption between the testosterone and placebo groups was 54.0 m (95% CI, 43.0-65.0 m), 46.7 m (95% CI, 12.6-80.9 m), and 2.70 mL/kg per min (95% CI, 2.68-2.72 mL/kg per min), respectively. Testosterone therapy was associated with a significant increase in exercise capacity as measured by units of pooled SDs (net effect, 0.52 SD; 95% CI, 0.10-0.94 SD). No significant adverse cardiovascular events were noted. CONCLUSIONS: Given the unmet clinical needs, testosterone appears to be a promising therapy to improve functional capacity in patients with HF. Adequately powered RCTs are required to assess the benefits of testosterone in this high-risk population with regard to quality of life, clinical events, and safety.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

May 1, 2012

Volume

5

Issue

3

Start / End Page

315 / 321

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Testosterone
  • Stroke Volume
  • Randomized Controlled Trials as Topic
  • Middle Aged
  • Male
  • Injections, Intramuscular
  • Humans
  • Heart Failure
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Toma, M., McAlister, F. A., Coglianese, E. E., Vidi, V., Vasaiwala, S., Bakal, J. A., … Ezekowitz, J. A. (2012). Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail, 5(3), 315–321. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965632
Toma, Mustafa, Finlay A. McAlister, Erin E. Coglianese, Venkatesan Vidi, Samip Vasaiwala, Jeffrey A. Bakal, Paul W. Armstrong, and Justin A. Ezekowitz. “Testosterone supplementation in heart failure: a meta-analysis.Circ Heart Fail 5, no. 3 (May 1, 2012): 315–21. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965632.
Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012 May 1;5(3):315–21.
Toma, Mustafa, et al. “Testosterone supplementation in heart failure: a meta-analysis.Circ Heart Fail, vol. 5, no. 3, May 2012, pp. 315–21. Pubmed, doi:10.1161/CIRCHEARTFAILURE.111.965632.
Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012 May 1;5(3):315–321.

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

May 1, 2012

Volume

5

Issue

3

Start / End Page

315 / 321

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Testosterone
  • Stroke Volume
  • Randomized Controlled Trials as Topic
  • Middle Aged
  • Male
  • Injections, Intramuscular
  • Humans
  • Heart Failure
  • Female